Clinical Trials Logo

Neoplasm, Prostate clinical trials

View clinical trials related to Neoplasm, Prostate.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03322020 Completed - Neoplasm, Prostate Clinical Trials

Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer

ADEBAR
Start date: March 21, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

For the treatment for intermediate- and high-risk prostate cancer, Cyberknife boost will be used after 4 weeks of intensity modulated radiotherapy to pelvis. The boost doses are 18 Gy and 21 Gy in 3 fractions, respectively. The investigators plan to evaluate the toxicity of two dose groups and decide the appropriate dose for Cyberknife boost. Also, PSA control will be evaluated.

NCT ID: NCT01819285 Completed - Neoplasm, Prostate Clinical Trials

Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer

Start date: February 1990
Phase: Phase 3
Study type: Interventional

Objectives I. Compare, in a randomized Phase III multi-institutional setting, symptom-free survival time of patients with asymptomatic carcinoma of the prostate (T0-4, N0-2, M0) not suited for local curative treatment who are randomly assigned to immediate vs. delayed endocrine intervention (orchiectomy or luteinizing hormone releasing hormone (LHRH) agonist therapy). II. Compare the overall survival of these two groups of patients. III. Compare the time to first evidence of distant progression (N4 or M1) of these two treatment groups. IV. Evaluate the prognostic significance of pretreatment laboratory data and monitor these parameters following endocrine therapy. V. Study the prognosis of various sub-groups of patients stratified according to performance status, local tumor extent, nodal status, and choice of endocrine treatment.

NCT ID: NCT01553188 Completed - Prostate Cancer Clinical Trials

AMG 386 and Abiraterone for Advanced Prostate Cancer

Start date: February 8, 2012
Phase: Phase 2
Study type: Interventional

Background: - Advanced prostate cancer is treated with surgery or drugs that lower the levels of androgens (male hormones) in the body. However, some cancers become resistant to this treatment. These types of cancers are known as castration-resistant prostate cancers. - Interfering with the growth of blood vessels that feed tumors can slow prostate cancer growth. Trebananib (AMG 386), a new anticancer drug, targets the blood vessels that feed tumors. It has been tested for different types of cancer, but not for prostate cancer. Researchers want to see if AMG 386 can slow disease progression in men with castration-resistant prostate cancer. AMG 386 will be given with abiraterone and prednisone, two drugs that are also used to treat advanced prostate cancer. Objectives: - To test the safety and effectiveness of AMG 386 with abiraterone for castration-resistant prostate cancer. Eligibility: - Men at least 18 years of age with castration-resistant prostate cancer. Design: - Participants will be screened with a physical exam, medical history, and imaging studies. Blood and urine samples will also be collected. - Participants will be separated into two groups. - The first group will have AMG 386 once per week for a total of four doses during a 28-day cycle. They will also take abiraterone once a day and prednisone twice a day, every day of the cycle. - The second group will not have AMG 386. They will take abiraterone once a day and prednisone twice a day, every day of the 28-day cycle. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will continue to take the study drugs as long as the disease does not progress and there are no severe side effects.